The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.

17 May 2025 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Spyridon Maragkoudakis

General Hospital St. George, Chania (Greece)

4 More presentations in this session

Presentation thumbnail

Cardioprotective strategies and outcomes in cancer therapy-related cardiac dysfunction: insights from a single-center study

Doctor I. Martins Moreira (Vila Real, PT)

Abstract Slides Video

Presentation thumbnail

Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors

Doctor M. Slieman (Tel Aviv, IL)

Abstract Slides Video

Presentation thumbnail

Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort

Doctor I. Araujo (Lisbon, PT)

Abstract Slides Video

Presentation thumbnail

Cardiotoxicity and immune checkpoint inhibitors: a heartfelt myth or the real deal?

Doctor S. Esteves (Lisbon, PT)

Abstract Slides Video

Access the full session

Session thumbnail

Interventions to improve outcomes in cardio-oncology

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025

You may be interested in

Congress Presentation

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

Congress Presentation

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

Congress Presentation

Anthracycline cardiotoxicity in patients receiving sodium-glucose co-transporter-2 inhibitors -is there any difference?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources